Can GLP-1 Help Prevent Alzheimer's? What the Evidence Shows (October 2026)

01 · The core answer

Does GLP-1 prevent Alzheimer's? Not proven

The honest answer is that nobody can yet say GLP-1 medicines prevent Alzheimer's disease. Some large database studies have found lower dementia rates among people taking these medicines. Some laboratory work suggests effects on brain inflammation and on how nerve cells respond to insulin. Trials in people who already have early Alzheimer's have not shown the clear cognitive benefit hoped for. Those are three different kinds of evidence, and none of them amounts to proof of prevention.

It also explains why no regulator has added dementia prevention to the licence of any GLP-1 medicine. For a deeper look at the research landscape, see our guide to GLP-1 agonists and Alzheimer's, and our page on Alzheimer's and GLP-1 research.

02 · Your decision

What should you do with this information?

If you are asking because you are worried about your own risk of dementia, the practical advice is the same as it was before GLP-1 headlines: speak to your GP, and focus on the measures with established benefit. Taking a prescription injection purely in the hope of protecting your memory is not something we would support, because the evidence does not justify it and every medicine carries side effects.

If you are asking because you already have a weight-related reason to consider treatment, the situation is different. Mounjaro is licensed for weight management in adults, and our prescribers assess that on the usual criteria. Any possible brain-health upside is, at best, a speculative extra and should never be the reason to start. You can read how the medicine is assessed on our weight loss clinic page, or look at the Mounjaro pen.

Every order is reviewed by a GPhC-registered prescriber, and the consultation is free. Unsuitable orders are refunded automatically.

03 · Why researchers are interested

Why researchers are interested in GLP-1 and the brain

GLP-1 is a natural gut hormone, and receptors for it are found not only in the gut and pancreas but also in parts of the brain. That biological fact is the starting point for the dementia hypothesis. If a medicine that acts on these receptors could calm inflammation or improve how brain cells use energy, it might in theory slow the damage seen in Alzheimer's.

The medicines themselves are well described in the product information. Tirzepatide, the active ingredient in Mounjaro, activates two natural gut-hormone receptors at once, GIP and GLP-1, helping regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ Those are the effects the licence is based on. Effects on dementia are a separate research question, and the product information does not claim them.

Researchers also note that type 2 diabetes and excess weight are linked with poorer health in many body systems. It is therefore hard to separate a direct effect on the brain from the indirect benefit of better metabolic health. This is one of the central difficulties in interpreting the data.

04 · Observational studies explained

Observational studies: why they are not proof

An observational study looks back at health records and compares people who took a medicine with people who did not. When such studies report lower dementia rates in the group taking GLP-1 medicines, it is natural to ask whether the medicine was responsible. The answer is: it might be, but the design cannot tell us.

The problem is that the two groups are rarely alike. People who are prescribed these medicines may differ in age, income, access to healthcare, other conditions, and how closely their doctors monitor them. Someone who is well enough to stay on an injection for years may also be healthier in ways that are never recorded. Researchers try to adjust for this statistically, but they can only adjust for what they have measured.

Observational findings are valuable for generating ideas. They are the reason proper trials are being run. But they sit low on the ladder of proof, and any page, headline or product that treats them as settled should be viewed with caution.

What would count as proof?

The stronger test is a randomised controlled trial in which people are assigned by chance to the medicine or to a dummy treatment, then followed for long enough to see who develops dementia. Dementia develops slowly, so these studies need many participants and many years. That is why the answer cannot be rushed.

05 · Trials so far

What the clinical trials have and have not shown

Trials of GLP-1 medicines in people who already have early Alzheimer's have so far been disappointing on their main cognitive goals, even where some biological markers moved in a helpful direction. A change in a marker in a blood test or scan is not the same as a person thinking, remembering or functioning better.

It is worth separating two ideas that are often blurred together:

• Treatment means slowing or reversing disease that has already started. The trials so far have not shown this.
• Prevention means lowering the chance that disease develops in the first place. This is the question the observational data hint at, and it is much harder to test.

A medicine can plausibly work for one and not the other. Damaged brain circuits cannot simply be rebuilt, so many scientists think any benefit would be strongest if treatment began long before symptoms. That is a hypothesis, not a result. Trials in people without diabetes, aimed at prevention, are the next step, and we would expect careful reporting when they conclude.

Different GLP-1 medicines also differ in structure, dose and how they enter the body. A finding for one product cannot be assumed to apply to another, including tirzepatide. You can see how we treat that question on our page about Mounjaro and Alzheimer's.

06 · Which GLP-1 is studied?

Which GLP-1 helps prevent dementia?

None can be named as proven. Several GLP-1 medicines, including semaglutide and older daily injections, have been looked at in dementia research, and tirzepatide is also of interest because it acts on two receptors. But interest is not a licence and not a result.

It matters to be clear about what each medicine is actually approved to do. Mounjaro is licensed in the UK for weight management in adults and for type 2 diabetes.¹ Wegovy is a once-weekly semaglutide pen with a dose ladder of 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, and 2.4mg is the licensed maintenance dose for weight management. Liraglutide is a daily injection supplied at 6mg/ml. None of those descriptions includes dementia prevention.

If you see a seller or social media account naming a particular GLP-1 as a memory or brain-health product, treat it as a red flag. Offering to supply without a consultation or prescription is unsafe whatever the claimed benefit, and counterfeit pens have been the subject of MHRA alerts.⁷

07 · What the evidence does show

What the evidence does show for Mounjaro

The results we can state with confidence concern weight. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

That is the evidence behind the licence, and it is the honest reason to consider the medicine. If dementia research eventually shows an added benefit, that will be welcome news. Today it is not a reason to start treatment, and nobody can responsibly promise it.

We take the same cautious line on other speculative claims, for example on GLP-1 and eczema and on lymphatic drainage.

08 · Protecting your brain now

What is the number one thing to prevent Alzheimer's?

There is no single action that prevents Alzheimer's, and anyone claiming a single vitamin or product slashes dementia risk should be questioned. Dementia risk is shaped by age, genetics and many everyday factors. The factors you can influence are well established in public health advice:

• Keeping blood pressure under control.
• Staying physically active most days.
• Not smoking and keeping alcohol moderate.
• Managing diabetes well if you have it.
• Treating hearing loss rather than ignoring it.
• Staying socially and mentally engaged.
• Protecting your head from injury.

These measures help your heart, your mood and your independence as well as your brain, so they are worthwhile whatever future trials show. Your GP can check blood pressure, cholesterol and blood sugar, and can arrange a memory assessment if you or a relative are noticing changes. Do not wait for a research breakthrough to act on what is already known.

09 · Risks, suitability and NHS access

Risks, who should avoid GLP-1 and NHS access

Any medicine started for an unproven reason still carries its normal risks. The most common side effects of Mounjaro are digestive: nausea, diarrhoea, vomiting, constipation and abdominal discomfort affect more than 1 in 10 people. The patient information leaflet lists them in full, along with who should not use the medicine.¹³ Our prescribers review your health history, current medicines and goals before supply. People using insulin or sulfonylureas may need their doses adjusted because of the risk of low blood sugar. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ This applies to the pill only: implants, coils and injections are unaffected.

If you notice a new symptom, including any change in memory or mood, tell your prescriber, and you can report suspected side effects through the MHRA Yellow Card scheme.¹⁹ Memory changes should always be assessed by a doctor rather than assumed to be a side effect or a sign of dementia. If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

On NHS access: Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Those criteria are about weight and related conditions, not dementia prevention. Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

10 · Reading future headlines

How to read the next GLP-1 and dementia headline

New studies will keep appearing, so it helps to have a few questions ready. Was it a trial with a comparison group, or a records study? Did it test prevention or treatment? Were the participants people like you, with or without diabetes? Was the result about real-life memory and daily function, or only about a laboratory marker? And who funded and reported it?

Be especially wary of language such as "breakthrough", "reverses" or "protects" when the underlying work was in animals, cells or database associations. Responsible reporting uses words like "may" and "could", and so do we.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹